Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Prostatic Neoplasms 3Multiple Myeloma 3Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Mouth Neoplasms 2Head and Neck Neoplasms 2Weight Loss 1Urinary Bladder Neoplasms 1Tobacco Use Cessation 1Thrombocytopenia 1Squamous Cell Carcinoma of Head and Neck 1Splenomegaly 1Smoking Cessation 1Neoplasm Metastasis 1Meningioma 1Lymphocytosis 1Lymphadenopathy 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Gynecologic Oncology Patient 1Gastrointestinal Neoplasms 1Fever 1Fatigue 1Fallopian Tube Neoplasms 1Depression 1Dental Caries 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

miridesap 3Dexamethasone 2Calcium Dobesilate 2venetoclax 1pomalidomide 1pegfilgrastim 1Technetium Tc 99m Pyrophosphate 1Technetium 1Surveys and Questionnaires 1Melphalan 1Interleukin-2 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Amyloidosis × Surveys and Questionnaires × Clear all
NCT01807286 2016-05-13

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Terminated
3 enrolled
Plasma cell

Amyloidosis, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡